These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
550 related articles for article (PubMed ID: 18078564)
1. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). Chen LS; Liao CS; Chang SH; Lai HC; Chen TH J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564 [TBL] [Abstract][Full Text] [Related]
2. [Colorectal cancer screening: advice from the Health Council of the Netherlands]. van Veen W; Mali WP Ned Tijdschr Geneeskd; 2009; 153():A1441. PubMed ID: 20003552 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Berchi C; Guittet L; Bouvier V; Launoy G Int J Technol Assess Health Care; 2010 Jan; 26(1):48-53. PubMed ID: 20059780 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Tsoi KK; Ng SS; Leung MC; Sung JJ Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075 [TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635 [TBL] [Abstract][Full Text] [Related]
6. Limitations of the faecal occult blood test in screening for colorectal cancer. Delcò F; Sonnenberg A Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of three FOBT protocols for colorectal cancer screening in Chinese--a multicenter study]. Li SR; Wang HH; Hu JC; Li N; Liu YL; Wu ZT; Zheng Y; Wang HH; Wu K; Ye H Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(10):697-700. PubMed ID: 15932737 [TBL] [Abstract][Full Text] [Related]
10. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence. Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M; J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257 [TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of immunochemical tests for colorectal cancer screening. Lejeune C; Le Gleut K; Cottet V; Galimard C; Durand G; Dancourt V; Faivre J Dig Liver Dis; 2014 Jan; 46(1):76-81. PubMed ID: 24012177 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer. Hamza S; Dancourt V; Lejeune C; Bidan JM; Lepage C; Faivre J Eur J Cancer; 2013 Aug; 49(12):2727-33. PubMed ID: 23601670 [TBL] [Abstract][Full Text] [Related]
13. Estimation of the optimal cut off point in a new immunological faecal occult blood test in a corporate colorectal cancer screening programme. Itoh M; Takahashi K; Nishida H; Sakagami K; Okubo T J Med Screen; 1996; 3(2):66-71. PubMed ID: 8849762 [TBL] [Abstract][Full Text] [Related]
14. Screening for colorectal cancer using faecal blood testing: varying the positive cut-off value. Edwards JB Pathology; 2005 Dec; 37(6):565-8. PubMed ID: 16373240 [No Abstract] [Full Text] [Related]
15. Potential impact of population-based colorectal cancer screening in Canada. Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods. Yamamoto M; Nakama H Hepatogastroenterology; 2000; 47(32):396-9. PubMed ID: 10791199 [TBL] [Abstract][Full Text] [Related]
17. High participation rates are not necessary for cost-effective colorectal cancer screening. Howard K; Salkeld G; Irwig L; Adelstein BA J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121 [TBL] [Abstract][Full Text] [Related]
18. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme. Faivre J; Dancourt V; Manfredi S; Denis B; Durand G; Gendre I; Bidan JM; Jard C; Levillain R; Jung S; Viguier J; Dorval E Dig Liver Dis; 2012 Aug; 44(8):700-4. PubMed ID: 22542582 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: a dynamic decision analytic approach. Wong SS; Leong AP; Leong TY Stud Health Technol Inform; 2004; 107(Pt 1):104-10. PubMed ID: 15360784 [TBL] [Abstract][Full Text] [Related]
20. Fecal occult blood testing when colonoscopy capacity is limited. Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]